Return to Clinical Studies

• Quantification of HDL2 and HDL3 cholesterol by the Vertical Auto Profile-II (VAP-II) methodology.
  
  
• Identification and cholesterol quantification of low density lipoprotein subclasses in young adults by VAP-II methodology.
  
  
• Quantification of cholesterol in all lipoprotein classes by the VAP-II method.
  
  
• Analysis of cholesterol in all lipoprotein classes by single vertical ultracentrifugation of fingerstick blood and controlled-dispersion flow analysis.
  
  

• The effect of simvastatin on triglyceride-rich lipoproteins in patients with type 2 diabetic dyslipidemia: A SILHOUETTE trial sub-study.
  
  
• Comparison of effects of simvastatin alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia.
  
  
• VAPII analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate.
  
  
• Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak article size in patients with mixed hyperlipidemia.
  
  
• Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia.
  
  
• Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: An exploratory analysis of archived samples using two commercially available techniques.
  
  
• Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia.
  
  
• Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (The SAFARI Trial).
  
  
• Effect of docosahexaenoic acid on lipoprotein subclasses in hyperlipidemic children (The EARLY study).
  
  
• Effectiveness of multiple antilipidemic agents on Vertical Auto Profile II guided treatment of dyslipoproteinemia.
  
  
• Relative effects of insulin resistance and protease inhibitor treatment on lipid and lipoprotein metabolism in HIV-Infected patients.
  
  

• Low adiponectin levels are associated with atherogenic dyslipidemia and lipid – rich plaque in non-diabetic coronary arteries.
  
  
• Metabolic syndrome phenotype in very obese women. Metabolic Syndrome and Related Disorders
  
  
• The relationship between insulin resistance and dyslipidemia in cigarette smokers.
  
  
• Lipid and insulin levels in obese children: changes with age and puberty.
  
  
• Multiple lipoprotein abnormalities associated with insulin resistance in healthy volunteers are identified by the Vertical Auto Profile–II methodology.
  
  
• Prevalence of Emerging Cardiovascular Risk Factors in Younger Individuals with a family history of premature coronary heart disease and low Framingham risk score.
  
  
• Racial differences in coronary artery calcification are not attributed to difference in lipoprotein particle sizes: The heart strategies concentrating on risk evaluation (Heart SCORE) study.
  
  
• Usefulness of low-density lipoprotein particle size measurement in cardiovascular disease prevention.
  
  
• Association of cholesterol subfractions and carotid lipid core measured by MRI.
  
  

• Clinical efficacy of two hypocaloric diets that vary in overweight patients with type 2 diabetes. Comparison of moderate fat versus carbohydrate reductions.
  
  
• Effects of moderate variations in macronutrient compositions on weight loss and reduction in cardiovascular disease risk in obese, insulin resistant adults.
  
  
• Biologic and quality-of-life outcomes from the Mediterranean lifestyle program.
  
  
• Effects of the amount and intensity of exercise on plasma lipoproteins.
  
  
• Snack chips fried in corn oil alleviate cardiovascular disease risk factors when substituted for low-fat or high-fat snacks.
  
  
• Flaxseed oil supplementation does not affect plasma lipoprotein concentration or particle size in human subjects.
  
  

• WellMed Poster  WellMed, a disease management company based out of Texas, utilizes the VAP in their IHD program. WellMed conducted a study with Thomas Jefferson University to see if treating unique VAP parameters, not found using routine cholesterol testing, could reduce cost of ER visits and reduce hospital beds days. The conclusions were significant for those patients who were managed with medications based on the VAP results. The findings indicated significant reduction in ER visits, reduced hospital bed days, increase drug compliance and cost savings were obtained showing substantial reductions in expense for these already established high risk patients.
  
  
• ACC LDL Poster  The University of Utah used the VAP to determine the clinical significance of LDL subclasses despite normal LDL levels at or below 100mg/dL. Following adverse outcomes and death this study showed that despite LDL level <100mg/dL if the patient still had a substantial concentration of LDL4+LDL3 (dense LDL, pattern B) then there was significant residual risk that left the patient at higher risk for a negative outcome. This data suggest that once patients have been managed to the NCEP target of <100mg/dL that LDL subclass data may further classify risk and select patients may require more aggressive LDL lowering or other agents added to improve subclass information.
  
  
• ACC ApoA1 Poster  The University of Utah used the VAP to determine the clinical significance of apolipoprotein AI (apoAI) despite normal HDL levels >40mg/dL. Following adverse outcomes and death this study showed that despite seemingly normal levels of HDL >40mg/dL, if the patient still had had low levels of apoAI these patients had negative outcomes. This study supports the growing data that not all HDL lipoproteins are equal and following subclasses of HDL may be a better marker of risk and subsequent target of therapy.
  
  

Return to Clinical Studies